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INTRODUCTION:  
The drug discovery process was beginning in nineteenth 
century; by John Langley in 1905 when he proposed the 
theory of receptive substances. The first rational 
development of synthetic drugs was carried out by Paul 
Ehrlich (father of modern chemotherapy). Ehrlich was 
awarded by Nobel Prize in 1908. In 1960 Hansch & 
Fujita introduced the concept of QSAR (quantitative 
structure–activity relationship).1 It is the mission of 
pharmaceutical research companies to take the path from 
understanding a disease to bringing a safe and effective 
new treatment to patients. Researchers work to: 
 validate these targets, 
 discover the right molecule (potential drug) to 
interact with the target chosen, 
 test the new compound in the lab and clinic for 
safety and efficacy and 
 Gain approval and get the new drug into the hands 
of doctors and patients. 
This whole process takes an average of 10-15 years. For 
every 5,000-10,000 compounds that enter the research 
and development pipeline, ultimately only one receives 
approval. 2 
DISCOVERY 
Pre-discovery 
Goal: Understand the disease and choose a target 
molecule. 
How: Scientists in pharmaceutical research companies, 
government, academic and for-profit research institutions 
contribute to basic research. 
Discovery Goal: Find a drug candidate. 
How: Create a new molecule or select an existing 
molecule as the starting point. 
Perform tests on that molecule and then optimize 
(change its structure) it to make it work better. 
Preclinical Goal: Test extensively to determine if the 
drug is safe enough for human testing. 
How: Researchers test the safety and effectiveness in the 
lab and in animal models. 
IND Goal: Obtain FDA approval to test the drug in 
humans. 
How: FDA reviews all preclinical testing and plans for 
clinical testing to determine if the drug is safe enough to 
move to human trials. 
Clinical Trials Goal: Test in humans to determine if the 
drug is safe and effective. 
How: Candidate drug is tested in clinical setting in three 
phases of trials, beginning with tests in a small group of 
healthy volunteers and moving into larger groups of 
patients. 
Review Goal: FDA reviews results of all testing to 
determine if the drug can be approved for patients to use. 
ABSTRACT:  
The research, development, and approval of a drug product is a continuous but lengthy process involving drug discovery, 
laboratory development, animal studies, clinical trials, and regulatory registration. This lengthy process is necessary to assure 
the effectiveness and safety of the drug product. It takes about 10-15 years to develop one new medicine from the time it is 
discovered to when it is available for treating patients. The average cost to research and develop each successful drug is 
estimated to be $800 million to $1 billion. This number includes the cost of the thousands of failures: For every 5,000- 10,000 
compounds that enter the research and development (R&D) pipeline, ultimately only one receives approval. These numbers 
defy imagination, but a deeper understanding of the R&D process can explain why so many compounds don’t make it and why 
it takes such a large, lengthy effort to get one medicine to patients. Ultimately, though, the process of drug discovery brings 
hope and relief to millions of patients. 
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How: The FDA reviews hundreds of thousands of pages 
of information, including all clinical and preclinical 
findings, proposed labeling and manufacturing plans. 
They may solicit the opinion of an independent advisory 
committee. 
Manufacturing Goal: Formulation, scale up and 
production of the new medicine. 
Ongoing Studies Goal: Monitor the drug as it is used in 
the larger population to catch any unexpected serious 
side effects. 
TOTAL 
How much: $800 million – $1 billion 
How long: 10 – 15 years [3] 
CURRENT TRENDS IN DRUG DISCOVERY 
Drug discovery and development can broadly follows 
two different approaches: structure based drug 
discovery and target-based discovery. In structure based 
if the compound displays desirable pharmacological 
activity, it is refined and developed further where as in 
target based strategy putative drug target is identified 
first. The potential target could be a receptor thought to 
be involved in a disease process or a critical enzyme, or 
another biologically, important molecule in the disease 
pathway. Target validation requires the confirmation that 
whether the particular target is involved in the disease or 
not.
 
Fig1. Showing the general steps in the discovery of a new drug for a specific disease state[1] 
 
DRUG DISCOVERY AND DEVELOPMENT 
The process of drug discovery and development can be 
broadly categorized into two subclasses: drug discovery 
and drug development. The drug discovery process can 
be described as the identification and validation of a 
disease target and the discovery and development of a 
chemical compound to interact with that target. Drug 
development involves satisfying all requirements that 
have to be met before a new compound can be deemed 
ready for testing in human subjects for the first time. 
Drug testing is achieved by preclinical and clinical trials. 
 
 
Fig 2: Steps for Drug discovery to development 
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BRANCHES OF SCIENCE IN VARIOUS STEPS OF DRUG DISCOVERY 
 
Fig 3: Showing the involvement of different topics and branches of science in various steps of drug discovery 
 
Drug Discovery Pipeline: The process by which a new 
drug is brought to market stage is referred to by a 
number of names – most commonly as the development 
chain or ―pipeline‖. The process of drug discovery takes 
about 15 years to complete, and the interesting feature is 
that it is complete only for few drug candidates as large 
number of parameters has to follow in order to pass from 
each and every step. 
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Fig 4: Showing the drug discovery pipeline and revels that how different process are interlinked. 
 
TARGET IDENTIFICATION – DISEASE 
MECHANISM 
Choose a molecule to target with a drug. Once they have 
enough understanding of the underlying cause of a 
disease, pharmaceutical researchers select a ―target‖ for a 
potential new medicine. A target is generally a single 
molecule, such as a gene or protein, which is involved in 
a particular disease. Target selection by the pharmacist 
depends on the disease on which he focused. Presently, 
G-protein coupled receptors (GPCR) are the predominant 
families addressed and more than 600 genes encoding 
GPCR have been identified. In humans, GPCR are 
responsible for about 30 disease including Diabetes 
insipedus, hypo and hyperthyroidism, retinis pigmentosa, 
several fertility disorders and even carcinoma. 
Approximately, 150 GPCRs found in human have 
unknown function. For the identification of target, In 
Silica approach is widely used, it’s a computer based 
technique to study the specific chemical responses in the 
body or target organism and tailoring combination of 
these to fit a treatment profile. Molecular Docking and 
Scoring techniques are also widely used; it involves 
computationally placing a virtual molecular structure 
into a binding site of a biological macromolecule. 
Various software has been developed-Auto Dock, Zdock, 
Dock & Docking Server. 1 
Pre-discovery: Understand the disease. Before any 
potential new medicine can be discovered, scientists 
work to understand the disease to be treated as well as 
possible, and to unravel the underlying cause of the 
condition. They try to understand how the genes are 
altered, how that affects the proteins they encode and 
how those proteins interact with each other in living 
cells, how those affected cells change the specific tissue 
they are in and finally how the disease affects the entire 
patient. This knowledge is the basis for treating the 
problem. 
Target Validation: Test the target and confirm its role 
in the disease. After choosing a potential target, scientists 
must show that it actually is involved in the disease and 
can be acted upon by a drug. Target validation is crucial 
to help scientists avoid research paths that look 
promising, but ultimately lead to dead ends. Researchers 
demonstrate that a particular target is relevant to the 
disease being studied through complicated experiments 
in both living cells and in animal models of disease. 
Lead Compound Identification: Find a promising 
molecule (a ―lead compound‖) that could become a drug 
Armed with their understanding of the disease, scientists 
are ready to begin looking for a drug. They search for a 
molecule, or ―lead compound,‖ that may act on their 
target to alter the disease course. If successful over long 
odds and years of testing, the lead compound can 
ultimately become a new medicine. 
There are a few ways to find a lead compound: 
Nature: Until recently, scientists usually turned to nature 
to find interesting compounds for fighting disease. 
Bacteria found in soil and moldy plants both led to 
important new treatments, for example. Nature still 
offers many useful substances, but now there are other 
ways to approach drug discovery. 
De novo: Thanks to advances in chemistry, scientists can 
also create molecules from scratch. They can use 
sophisticated computer modeling to predict what type of 
molecule may work. 
High-throughput Screening: This process is the most 
common way that leads are usually found. Advances in 
robotics and computational power allow researchers to 
test hundreds of thousands of compounds against the 
target to identify any that might be promising. 
Based on the results, several lead compounds are usually 
selected for further study. 
Biotechnology: Scientists can also genetically engineer 
living systems to produce disease-fighting biological 
molecules. 
Early Safety Tests: Perform initial tests on promising 
compounds. Lead compounds go through a series of tests 
to provide an early assessment of the safety of the lead 
compound. Scientists test Absorption, Distribution, 
Metabolism, Excretion and Toxicological (ADME/Tox) 
properties, or ―pharmacokinetics,‖ of each lead. 
Successful drugs must be: 
 absorbed into the bloodstream, 
 distributed to the proper site of action in the body, 
 metabolized efficiently and effectively, 
 successfully excreted from the body and 
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 demonstrated to be not toxic. 
These studies help researchers prioritize lead compounds 
early in the discovery process. ADME/Tox studies are 
performed in living cells, in animals and via 
computational models. 
Lead Optimization: Alter the structure of lead 
candidates to improve properties, Lead compounds that 
survive the initial screening are then ―optimized,‖ or 
altered to make them more effective and safer. By 
changing the structure of a compound, scientists can give 
it different properties. For example, they can make it less 
likely to interact with other chemical pathways in the 
body, thus reducing the potential for side effects. 
Hundreds of different variations or ―analogues‖ of the 
initial leads are made and tested. Even at this early stage, 
researchers begin to think about how the drug will be 
made, considering formulation, delivery mechanism and 
large-scale manufacturing. 
Preclinical Testing: Lab and animal testing to determine 
if the drug is safe enough for human testing With one or 
more optimized compounds in hand, researchers turn 
their attention to testing them extensively to determine if 
they should move on to testing in humans. 
Scientists carry out in vitro and in vivo tests. In vitro tests 
are experiments conducted in the lab, usually carried out 
in test tubes and beakers and in vivo studies are those in 
living cell cultures and animal models. 
Preclinical Toxicology Testing and IND Application: 
Preclinical testing analyzes the bioactivity, safety, and 
efficacy of the formulated drug product. This testing is 
critical to a drug’s eventual success and, as such, is 
scrutinized by many regulatory entities. During the 
preclinical stage of the development process, plans for 
clinical trials and an Investigative New Drug (IND) 
application are prepared.  
The main stages of preclinical toxicology testing are: 
Acute Studies: Acute tox studies look at the effects of 
one or more doses administered over a period of up to 24 
hours. The goal is to determine toxic dose levels and 
observe clinical indications of toxicity. Usually, at least 
two mammalian species are tested. Data from acute tox 
studies helps determine doses for repeated dose studies 
in animals and Phase I studies in humans. 
Repeated Dose Studies: Depending on the duration of 
the studies, repeated dose studies may be referred to as 
sub-acute, sub-chronic, or chronic. The specific duration 
should anticipate the length of the clinical trial that will 
be conducted on the new drug. Again, two species are 
typically required. 
Genertic Toxicity Studies: These studies assess the 
likelihood that the drug compound is mutagenic or 
carcinogenic. Procedures such as the Ames test 
(conducted in bacteria) detect genetic changes. DNA 
damage is assessed in tests using mammalian cells such 
as the Mouse Micronucleus Test. The Chromosomal 
Aberration Test and similar procedures detect damage at 
the chromosomal level. 
Reproductive Toxicity Studies: Segment I reproductive 
tox studies look at the effects of the drug on fertility. 
Segment II and III studies detect effects on embryonic 
and post-natal development. In general, reproductive tox 
studies must be completed before a drug can be 
administered to women of child-bearing age. 
Carcinogenicity Studies: Carcinogenicity studies are 
usually needed only for drugs intended for chronic or 
recurring conditions. They are time consuming and 
expensive, and must be planned for early in the 
preclinical testing process. 
Toxicokinetic Studies: These are typically similar in 
design to PK/ADME studies except that they use much 
higher dose levels. They examine the effects of toxic 
doses of the drug and help estimate the clinical margin of 
safety.   
Pre Clinical Evolutions (Animal Studies) 
The candidate drug is subjected to extensive 
pharmacological testing invitro and invivo on animal 
models (mice, rats, pigs, dogs). Major areas of research 
are: 
1. Acute, substance and chronic toxicity studies 
(toxicity profile) 
2. Therapeutic index (safety and efficacy evolution): it 
is the ratio of median lethal dose (LD50) for a drug 
to the median effective dose (ED50). 
3. Absorption, Distribution, Metabolism & Elimination 
ADME studies (Pharmacokinetics)  
Pharmacokinetics and Drug Disposition 
Pharmacokinetic (PK) or ADME 
(Absorption/Distribution/Metabolism/Excretion) studies 
provide useful feedback for formulation scientists. PK 
studies yield parameters such as AUC (area under the 
curve), Cmax (maximum concentration of the drug in 
blood), and Tmax (time at which Cmax is reached). Later 
on, this data from animal PK studies is compared to data 
from early stage clinical trials to check the predictive 
power of animal models. 
Drug development phases 
There are three major phases in drug development: 
1. Pre-clinical research and development 
2. Clinical research and development 
3. After the compound is on the market, a possible ―post-
marketing‖ Phase 3 
Clinical Trials 
Investigational New Drug (IND) Application and 
Safety 
File IND with the FDA before clinical testing can begin; 
ensure safety for clinical trial volunteers through an 
Institutional Review Board. 
Before any clinical trial can begin, the researchers must 
file an Investigational New Drug (IND) application with 
the FDA. The application includes the results of the 
preclinical work, the candidate drug’s chemical structure 
and how it is thought to work in the body, a listing of any 
side effects and manufacturing information. The IND 
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also provides a detailed clinical trial plan that outlines 
how, where and by whom the studies will be performed. 
In addition to the IND application, all clinical trials must 
be reviewed and approved by the Institutional Review 
Board (IRB) at the institutions where the trials will take 
place. Statisticians and others are constantly monitoring 
the data as it becomes available. The FDA or the sponsor 
company can stop the trial at any time if problems arise. 
Finally, the company sponsoring the research must 
provide comprehensive regular reports to the FDA and 
the IRB on the progress of clinical trials. 
Phase 1 Clinical Trial: In Phase 1 trials the candidate 
drug is tested in people for the first time. These studies 
are usually conducted with about 20 to 100 healthy 
volunteers. The main goal of a Phase 1 trial is to discover 
if the drug is safe in humans. Researchers look at the 
pharmacokinetics of a drug: How is it absorbed? How is 
it metabolized and eliminated from the body? They also 
study the drug’s Pharmacodynamic: Does it cause side 
effects? Does it produce desired effects? These closely 
monitored trials are designed to help researchers 
determine what the safe dosing range is and if it should 
move on to further development. 
Phase 2 Clinical Trial: In Phase 2 trials researchers 
evaluate the candidate drug’s effectiveness in about 100 
to 500 patients with the disease or condition under study, 
& examine the possible short-term side effects & risks 
associated with the drug. They also strive to answer these 
questions: Is the drug working by the expected 
mechanism? Does it improve the condition in question? 
Researchers also analyze optimal dose strength and 
schedules for using the drug. If the drug continues to 
show promise, they prepare for the much larger Phase 3 
trials. 
Phase 3 Clinical Trial 
In Phase 3 trials researchers study the drug candidate in a 
larger number (about 1,000-5,000) of patients to generate 
statistically significant data about safety, efficacy and the 
overall benefit-risk relationship of the drug. This phase 
of research is keys in determining whether the drug is 
safe and effective. It also provides the basis for labeling 
instructions to help ensure proper use of the drug. During 
the Phase 3 trial , researchers are also conducting many 
other critical studies, including plans for full scale 
production and preparation of the complex application 
required for FDA approval. 
PHASE 0, 2A AND 2B TRIALS 
Phase 0 Trial: The FDA has recently endorsed ―micro 
dosing‖ or the ―phase 0 trial,‖ which allows researchers 
to test a small drug dose in fewer human volunteers to 
quickly weed out drug candidates that are metabolically 
or biologically ineffective. 
Phase 2a and 2b Trials: Sometimes combined with a 
phase 1 trial, a phase 2a trial is aimed not only at 
understanding the safety of a potential drug, but also 
getting an early read on efficacy and dosage in a small 
group of patients. The resulting phase 2b trial would be 
designed to build on these results in a larger group of 
patients for the sake of designing a rigorous and focused 
phase 3 trials.4 
 
5,000 to 10,000 Compounds Yield 1 New Drug to Market 
Step Number of 
Compounds 
Years 
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
Discovery – 
identifying & 
screening 
5,000—10,000                 
Preclinical 
Testing - in 
laboratory and 
animal studies 
250                 
Phase I - Safety 
and dosage 
evaluated on 20-
100 healthy human 
volunteers 
5                  
Phase II - Efficacy 
and side effects 
tested on 100-500 
patient volunteers 
1                 
Phase III -  
Effectiveness and 
reactions to long-
term use tested on 
1,000 to 5,000 
patient volunteers 
1                 
FDA Review and 
Approval  
1                 
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New Drug Application (NDA) and Approval 
Once all three phases of the clinical trials are complete, 
the sponsoring company analyzes all of the data. Submit 
application for approval to FDA. The NDA includes all 
of the information from the previous years of work, as 
well as the proposals for manufacturing and labeling of 
the new medicine. 
FDA experts review all the information included in the 
NDA to determine if it demonstrates that the medicine is 
safe and effective enough to be approved. Following 
rigorous review, the FDA can either 1) approve the 
medicine, 2) send the company an ―approvable‖ letter 
requesting more information or studies before approval 
can be given, or 3) deny approval. 
Review of an NDA may include an evaluation by an 
advisory committee, an independent panel of FDA-
appointed experts who consider data presented by 
company representatives and FDA reviewers. 
Committees then vote on whether the FDA should 
approve an application, and under what conditions.  
NDA Forms and Electronic Submissions: 
 Form FDA-356h.   Application to Market a New 
Drug, Biologic, or An Antibiotic Drug For Human 
Use 
 Form FDA-3397.   User Fee Cover Sheet 
 Form FDA-3331.  New Drug Application Field 
Report. 5 
Review Time Frames (21 CFR 314.100):  
This time frame includes:  
 Within 180 days of receipt of an application, the 
FDA will review and issue an approval, 
approvable, or not approvable letter. This 180-day 
period is called the ―review-clock‖  
 During the review period an applicant may 
withdraw an application (21 CFR 314-65) and later 
resubmit it.  
 The time period may be extended by mutual 
agreement between the FDA and the applicant or as 
the result of submission of a major amendment (21 
CFR 314.60) 6 
 
 
Review Process of NDA: 
7 
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BENEFIT VS. RISK: After close to a decade of testing, 
the company files a New Drug Application (NDA) with 
the FDA. Reported in the NDA are all the data gathered 
from all studies of the potential new drug, including the 
preclinical as well as clinical findings. In particular, it 
uses the information in the NDA to try to address three 
major concerns: 
1) Because no drug has zero risk, the FDA must 
determine whether the benefits of the drug outweigh 
the risk, i.e., is the drug effective for its proposed 
use, and has an acceptable balance between benefits 
and risks been achieved? 
2) Based on its assessment of risk and benefit, the FDA 
must decide what information the package inserts 
should contain to guide physicians in the use of the 
new drug. 
3) Finally, the FDA must assess whether the methods 
used to manufacture the drug and ensure its quality 
are adequate to preserve the drug’s identity, strength 
and purity. 
Post Approval Activities 
Manufacturing: Going from small-scale to large-scale 
manufacturing is a major undertaking. In many cases, 
companies must build a new manufacturing facility or 
reconstruct an old one because the manufacturing 
process is different from drug to drug. Each facility must 
meet strict FDA guidelines for Good Manufacturing 
Practices (GMP). 
Ongoing Studies and Phase 4 Trials: Research on a 
new medicine continues even after approval. As a much 
larger number of patients begin to use the drug, 
companies must continue to monitor it carefully and 
submit periodic reports, including cases of adverse 
events, to the FDA. In addition, the FDA sometimes 
requires a company to conduct additional studies on an 
approved drug in ―Phase 4‖ studies.  
Approval: Once FDA approves the NDA, the new 
medicine becomes available for physicians to prescribe. 
The company must continue to submit periodic reports to 
FDA, including any cases of adverse reactions and 
appropriate quality-control records. For some medicines, 
FDA requires additional studies (Phase IV) to evaluate 
long-term effects. 
Discovering & developing safe and effective new 
medicines is a long, difficult and expensive process. The 
research-based pharmaceutical industry will invest 
$12.6 billion in research and development this year, and 
that investment has been doubling every five years. 8 
Conclusion: The discovery and development of new 
medicines is a long, complicated process. Each success is 
built on many, many prior failures. Advances in 
understanding human biology and disease are opening up 
exciting new possibilities for breakthrough medicines. At 
the same time, researchers face great challenges in 
understanding and applying these advances to the 
treatment of disease. These possibilities will grow as our 
scientific knowledge expands and becomes increasingly 
complex. Research-based pharmaceutical companies are 
committed to advancing science and bringing new 
medicines to patients. 
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